Denemek ALTIN - Özgür
Eschewing Myopic Attitude Towards Eye Health
BioSpectrum Asia
|July 2022
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia. Thus, early intervention is crucial in the control of myopia and the onus is to be equally distributed between the stakeholders of the eye healthcare ecosystem. Studie have shown that the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. Let's explore the available early interventions that could effectively tackle the rising incidents of myopia, especially in the young.
Uncorrected myopia remains the leading cause of distance vision impairment globally, and its rising prevalence could cost billions of dollars in lost productivity in the coming decades. A hallmark study by the Brien Holden Vision Institute (BHVI) in Australia predicts that by 2050, over half the world's population or 52 per cent will be myopic.
Direct costs of myopia in Asia alone have been estimated at $328 billion every year, with an additional $244 billion in productivity losses associated with myopia.
Studies have shown the increased intensity of educational pressures in young children has coincided with the rapid rise in myopia cases in Asian countries in recent decades. In many East Asian countries, myopia is a major public health concern that affects between 80 and 90 per cent of high school graduates, of which about 10 to 20 per cent have sight-threatening pathologic myopia.
In particular, with quarantine practices in place during the onset of COVID-19 and children attending online classes over electronic devices, the rise in myopia has been sharp. According to a recent study, more children have developed myopia as an unexpected side-effect of the pandemic.
Bu hikaye BioSpectrum Asia dergisinin July 2022 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
BioSpectrum Asia'den DAHA FAZLA HİKAYE
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits
US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation
US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio
Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema
A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing
Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO
Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
IIT-D and AIIMS develop swallowable microdevice for microbiome study
Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.
1 min
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Ambitious research to develop multivalent vaccines against multiple deadly filoviruses
Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.
1 min
BioSpectrum Asia Feb 2026
Translate
Change font size
